Loading blog post…
A complete guide to azelaic acid in skincare — its dicarboxylic acid origin from Pityrosporum ovale fermentation, the dual mechanisms targeting acne (antibacterial + comedolytic + anti-inflammatory) and hyperpigmentation (selective tyrosinase inhibition in hyperactive melanocytes), why it causes less PIH risk than other depigmenting agents, the evidence for 15% and 20% formulations in melasma and rosacea, how to use 10% OTC vs 15% Rx formulations, and who is the ideal azelaic acid patient.
· By MedSpot Editorial · 5 min read
Azelaic acid is one of the most clinically versatile active ingredients — simultaneously effective for acne, rosacea, and hyperpigmentation through distinct mechanisms for each condition. It is underutilized in many skincare routines relative to its evidence base. Here is the complete guide.
Azelaic acid (nonanedioic acid) is a naturally occurring dicarboxylic acid — a nine-carbon straight-chain diacid produced by Malassezia species (formerly Pityrosporum ovale), the commensal yeast that normally inhabits skin. It is found in trace amounts on normal skin as part of the microbiome's metabolic output.
For cosmetic and pharmaceutical use, azelaic acid is produced synthetically (ozonolysis of oleic acid from wheat, rye, or barley). It is a small molecule (188 Da) with good stratum corneum penetration compared to macromolecular actives.
1. Antibacterial: Azelaic acid inhibits Cutibacterium acnes (formerly P. acnes) protein synthesis — bacteriostatic at the concentrations used in skincare (20%). Unlike benzoyl peroxide, it does not produce reactive oxygen species, so it does not cause oxidative stress to surrounding tissue. Importantly, no C. acnes resistance to azelaic acid has been documented — unlike antibiotic resistance, a significant clinical advantage.
2. Comedolytic: Normalizes the abnormal keratinization in follicular infundibulum — the process that produces the plug in comedone formation. Similar mechanism to retinoids but less potent; does not cause retinization.
3. Anti-inflammatory: Inhibits reactive oxygen species (ROS) generation by neutrophils and reduces pro-inflammatory cytokine production at the follicle — addressing the inflammatory component of acne independently of its antibacterial action.
Azelaic acid is FDA-approved (as 15% gel and 20% cream) for papulopustular rosacea. Its mechanisms:
Selective tyrosinase inhibition in hyperactive melanocytes: Azelaic acid inhibits tyrosinase — but crucially, it is selectively cytotoxic to abnormally active melanocytes (as in melasma) and minimally affects normal melanocytes.
This selectivity is azelaic acid's most important depigmenting property:
Baliña LM, Graupe K. (1991). The treatment of melasma — 20% azelaic acid versus 4% hydroquinone cream. International Journal of Dermatology, 30(12), 893–895.
Randomized study comparing 20% azelaic acid cream to 4% hydroquinone cream in melasma: both produced equivalent improvement in pigmentation scores over 24 weeks. Azelaic acid had a better tolerability profile, fewer irritation-related adverse events.
This study established azelaic acid as a genuine hydroquinone alternative — not a weaker substitute but an equivalent one with different tolerability characteristics.
Thiboutot D, et al. (2003). Azelaic acid 15% gel (Finacea) in the treatment of moderate papulopustular rosacea. Journal of the American Academy of Dermatology, 48(6), 836–845.
Multicenter RCT establishing 15% azelaic acid gel (Finacea) as effective for papulopustular rosacea — significant reduction in inflammatory lesion counts and erythema, superior to vehicle. This is the pivotal trial supporting the FDA approval.
Strong clinical evidence supports 20% azelaic acid cream for mild-to-moderate inflammatory acne, comparable to topical antibiotic agents (erythromycin, clindamycin) in some comparative studies — with the significant advantage of no resistance potential.
| Formulation | Concentration | Indication | Access |
|---|---|---|---|
| OTC creams/serums | 5–10% | General brightening; mild acne; PIH maintenance | OTC |
| Finacea gel | 15% | Rosacea (FDA-approved) | Rx |
| Skinoren cream | 20% | Acne; melasma (outside US) | Rx in many countries |
| Azelex cream | 20% | Acne (FDA-approved) | Rx |
OTC 10%: Evidence for 10% azelaic acid is more limited than 15–20%. Many OTC products use 10% or below; some clinical benefit for brightening and mild acne is plausible, but the pivotal RCTs used 15–20%. Reasonable as a maintenance or adjunctive treatment; less reliable as monotherapy.
Prescription access via telehealth: 15–20% azelaic acid is commonly prescribed through dermatology telehealth platforms — it has a strong safety profile and is appropriate for remote prescription.
Azelaic acid is one of the most broadly tolerable prescription-strength actives:
The main limitation: Efficacy at OTC concentrations (5–10%) is more modest. The meaningful evidence base is at 15–20%, which requires a prescription.
Twice daily is the standard protocol for prescription formulations (gel or cream). Once daily is also used in maintenance.
With moisturizer: Apply to clean skin; follow with moisturizer if using the gel (which can dry the skin somewhat). The cream formulation is self-moisturizing.
With other actives: Azelaic acid is compatible with niacinamide, tranexamic acid, vitamin C, and SPF. It is not pH-sensitive (works at neutral pH), so no timing concerns with most actives. It can be used on retinoid nights without conflict (unlike AHAs).
Realistic timeline: 4–6 weeks for acne/rosacea improvement; 8–12 weeks for meaningful pigmentation reduction.
Looking for an azelaic acid prescription or acne/rosacea consultation? Browse med spa providers on MedSpot →